| Biotech Co.* (Country; Symbol) |
Pharma Co. Country) |
Type/Product Area | Terms/Details (Date) |
| JUNE | |||
| Apthera Inc.* | Kwang Dong Pharmaceutical Co. Ltd. (South Korea) | Licensing agreement for NeuVax in South Korea for breast cancer | Apthera will receive equity investments as well as milestone and royalty payments (6/4) |
| Elusys Therapeutics* | Lonza Sales AG (Switzerland) | Agreement for the production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of anthrax infection | Lonza will provide process development services and manufacturing capacity for that product using Lonza's GS Gene Expression System (6/16) |
| JULY | |||
| BioAlliance Pharma SA (France; Paris:BIO) | H. Lundbeck A/S (Denmark) | Agreement to co-promote the antidepressant Seroplex | Efforts will be aimed at core health care partners; financial terms were not disclosed (7/21) |
| NewBridge Pharmaceuticals* | Axcan Pharma Inc. (Canada) | Exclusive license and supply agreement for Pylera, a 3-in-1 capsule therapy for the treatment of Helicobacter pylori | NewBridge is entitled to obtain exclusive rights in certain markets where it obtains required regulatory approvals and launches the product (7/22) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
To read more on related topics, click on one of the words below.